- Home
- DHF vs BNR Comparison
DHF vs BNR Comparison
Compare DHF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | BNR |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 216.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DHF | BNR |
|---|---|---|
| Price | $2.54 | $35.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 451.1K | 34.1K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $2.06 | $2.18 |
| 52 Week High | $2.39 | $41.72 |
Technical Indicators
Market Signals| Indicator | DHF | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 64.86 |
| Support Level | $2.47 | $35.00 |
| Resistance Level | $2.54 | $41.72 |
| Average True Range (ATR) | 0.02 | 3.51 |
| MACD | 0.00 | 0.68 |
| Stochastic Oscillator | 70.00 | 71.00 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.